How does the extended PFS data (>4-year median) with taletrectinib impact your choice of frontline therapy and subsequent sequencing approach for ROS1+ NSCLC?

The newest taletrectinib data, in my mind, establishes this as my current (and preferred) first-line option for patients with ROS1+ NSCLC. With the totality of data available, I do not believe crizotinib or entrectinib has a role in the management of patients with ROS1+ NSCLC. Taletrectinib has exce...

Overall favorable and is the preferred 1L option for newly diagnosed advanced ROS1+NSCLC, and also the preferred 2L option in my practice currently for those who were started on older approved agents such as crizotinib. Better balance between efficacy and toxicity profile compared to other available...